METHODS AND COMPOSITIONS RELATING TO EXOSOMES
The disclosure provides compositions comprising exosome subpopulations, and methods of their use in subjects having certain disorders including lung disorders, cardiovascular disorders, renal disorders and ischemic neural disorders. The disclosure provides compositions comprising exosomes and methods of use thereof in the treatment and/or prevention of various diseases or disorders. 25 Accordingly, one aspect of the disclosure provides an isolated exosome. In some embodiments, the isolated exosome comprises one or more markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3, SMAD5 and CD105, and/or the isolated exosome does not comprise one or more markers selected from the group consisting of FLOT1, CD9, CD81, CAV1, EGFR, AKT1 and AKT2. In some embodiments, 30 the isolated exosome comprises 2, 3, 4, 5, 6, 7 or 8 markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3> SMAD5 and CD105..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 10. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MITSIALIS S ALEXANDER [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-10, Last update posted on www.tib.eu: 2023-11-06, Last updated: 2023-11-10 |
|---|
| Patentnummer: |
CA2949083 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005772826 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005772826 | ||
| 003 | DE-627 | ||
| 005 | 20231110090628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA005772826 | ||
| 035 | |a (EPA)CA2949083 | ||
| 035 | |a (EPA)54554566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MITSIALIS S ALEXANDER |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHODS AND COMPOSITIONS RELATING TO EXOSOMES |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-10, Last update posted on www.tib.eu: 2023-11-06, Last updated: 2023-11-10 | ||
| 520 | |a The disclosure provides compositions comprising exosome subpopulations, and methods of their use in subjects having certain disorders including lung disorders, cardiovascular disorders, renal disorders and ischemic neural disorders. The disclosure provides compositions comprising exosomes and methods of use thereof in the treatment and/or prevention of various diseases or disorders. 25 Accordingly, one aspect of the disclosure provides an isolated exosome. In some embodiments, the isolated exosome comprises one or more markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3, SMAD5 and CD105, and/or the isolated exosome does not comprise one or more markers selected from the group consisting of FLOT1, CD9, CD81, CAV1, EGFR, AKT1 and AKT2. In some embodiments, 30 the isolated exosome comprises 2, 3, 4, 5, 6, 7 or 8 markers selected from the group consisting of ALIX, TSG101, TGFBR2, SMAD1, SMAD2, SMAD3> SMAD5 and CD105. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KOUREMBANAS STELLA |4 aut | |
| 700 | 0 | |a SDRIMAS KONSTANTINOS |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 10. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:10 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/54554566/publication/CA2949083A1?q=CA2949083 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 10 |c 10 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 10 |c 10 | ||